Title: Interleukin-3
Additional Names: Multipotent colony stimulating factor; IL-3; multi-CSF
Literature References: Hematopoietic growth factor that promotes the survival, differentiation and proliferation of multipotent hematopoietic stem cells and of committed progenitor cells of the megakaryocyte, granulocyte-macrophage, erythroid, eosinophil, basophil and mast cell lineages. Enhances thrombopoiesis, phagocytosis, antibody-mediated cellular cytotoxicity and eosinophil metabolism. Species-specific, variably glycosylated peptide; human: 14-28 kDa, 133 amino acids; murine: 22-32 kDa, 140 amino acids. Produced primarily by activated T-lymphocytes; also by natural killer cells and mast cells. Undetectable in normal serum, postulated to be involved in the immune response. Purification from murine myelomonocytic leukemia cells (WEHI-3): J. N. Ihre et al., J. Immunol. 129, 2431 (1982). Cloning of murine IL-3: M. C. Fung et al., Nature 307, 233 (1984); T. Yokota et al., Proc. Natl. Acad. Sci. USA 81, 1070 (1984); of human: Y.-C. Yang et al., Cell 47, 3 (1986). Review of molecular and cellular biology: C. F. Morris et al., Immunol. Ser. 49, 177-214 (1990); of structure and function: A. Lindemann, R. Mertelsmann, Cancer Invest. 11, 609-623 (1993). Review of clinical pharmacology: A. Ganser, ibid. 212-218.
Derivative Type: Muplestim
CAS Registry Number: 148641-02-5
Manufacturers' Codes: SDZ-ILE-964
Trademarks: Hemokine (Novartis)
Literature References: Human IL-3 produced in E. coli by recombinant DNA technology. Clinical pharmacokinetics: B. Biesma et al., Cancer Res. 53, 5915 (1993). Clinical evaluation in chemotherapy induced neutropenia: S. Kudoh et al., Cancer Chemother. Pharmacol. 38, Suppl., S89 (1996).
Derivative Type: Fusion protein with GM-CSF
CAS Registry Number: 137463-76-4
Additional Names: PIXY321; GM-CSF/IL-3 fusion protein
Literature References: Hybrid molecule consisting of the active domains of human GM-CSF and IL-3 coupled by a flexible amino acid sequence. Construction and expression in yeast: B. M. Curtis et al., Proc. Natl. Acad. Sci. USA 88, 5809 (1991). Evaluation in cancer patients: S. Vadhan-Raj et al., J. Clin. Oncol. 12, 715 (1994). Review: idem, Stem Cells 12, 253-261 (1994).
Therap-Cat: Hematopoietic; antineutropenic.
Keywords: Antineutropenic; Hematopoietic. |